Proactive Investors - Run By Investors For Investors

Imugene Limited on road to raising

Imugene Limited on road to raising

Clinical stage immuno-oncology company Imugene Limited (ASX:IMU) has been granted a trading halt by the ASX, with its shares placed in pre-open.

Imugene is currently preparing to release capital raising details.

The company is developing HER-2+ gastric and breast cancer immunotherapies.

The halt will remain in place until the opening of trade on Wednesday 9th September 2015, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full IMU profile View Profile

Imugene Ltd Timeline

Newswire
September 07 2015

Related Articles

Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
porcupine
November 30 2018
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
blood
December 03 2018
Feraccru already has EU approval while in Switzerland the drug can be used for iron deficiency anaemia in adults with inflammatory bowel disease
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use